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ABSTRACT
The proline-rich homeodomain protein (PRH/Hex)
regulates transcription by binding to specific DNA
sequences and regulates mRNA transport by bind-
ing to translation initiation factor eIF4E. Protein
kinase CK2 plays multiple roles in the regulation of
gene expression and cell proliferation. Here, we
show that PRH interacts with the b subunit of CK2
in vitro and in cells and that CK2 phosphorylates
PRH. Phosphorylation of PRH by CK2 inhibits the
DNA binding activity of this protein and depho-
sphorylation restores DNA binding indicating
that this modification acts as a reversible switch.
We show that phosphorylation of the homeodomain
is sufficient to block DNA binding and we identify
two amino acids within this the domain that
are phosphorylated by CK2: S163 and S177. Site-
directed mutagenesis demonstrates that mutation
of either of these residues to glutamic acid partially
mimics phosphorylation but is insufficient to com-
pletely block DNA binding whereas an S163E/S177E
double mutation severely inhibits DNA binding.
Significantly, the S163E and S177E mutations and
the S163E/S177E double mutation all inhibit the abil-
ity of PRH to regulate transcription in cells. Since
these amino acids are conserved between many
homeodomain proteins, our results suggest that
CK2 may regulate the activity of several homeodo-
main proteins in this manner.
INTRODUCTION
Phosphorylation of transcription factors forms a link
between signal transduction pathways and the expression
of genes. Phosphorylation can control the activity of tran-
scription factors by altering their DNA-binding aﬃnity,
sub-cellular compartmentalization, stability or ability
to form protein–protein interactions (1). Protein kinase
CK2 (formerly casein kinase II) is a ubiquitously
expressed kinase that regulates multiple proteins involved
in transcription, signalling, cell proliferation and DNA
repair (2). In general, CK2 has growth promoting and
oncogenic properties. CK2 is a tetramer consisting of
a and a0 subunits (forming the catalytic domain) and a
b subunit dimer (forming the regulatory domain). CK2
usually phosphorylates serine and threonine residues and
the consensus phosphorylation site is (S/T)XXD/E where
X represents any amino acid (3). The CK2b subunit is
important in the assembly of CK2, enzyme stability and
enzyme activity. It can interact with modulators of CK2
activity as well as with CK2 substrates and is thought
to be required for the selection of substrates. CK2b
also has roles that are independent of CK2 enzymatic
activity and these include the negative regulation of cell
proliferation (4).
A number of homeodomain proteins that control
transcription are regulated by CK2 including the
Drosophila homeodomain proteins Antennapaedia (5),
Eve (6) and En (7,8) and the mammalian homeodomain
proteins Hoxb-6 (9), Cut/CDP (10), Csx/Nk2.5 (11) and
SIX1 (12). Phosphorylation of homeodomain proteins by
CK2 at sites outside the homeodomain has been shown to
inﬂuence protein–protein interactions (5,6), DNA-binding
aﬃnity (5,8) and protein traﬃcking (7). In some cases
CK2 phosphorylation of these proteins has an eﬀect on
cell-cycle progression. For example, Six1 plays a role in
regulation of the G2/M cell-cycle checkpoint (12).
Phosphorylation of Six1 by CK2 at sites located outside
the homeodomain occurs during interphase and mitosis.
Phosphorylation inhibits the DNA-binding activity of
Six1 and this may contribute to regulation of the G2/M
checkpoint (12). Few homeodomain proteins are phos-
phorylated by CK2 at sites within the homeodomain.
However, the Csx/Nk2.5 protein is phosphorylated at a
consensus CK2 site located within the homeodomain and
this site is conserved in the Nk and Six class homeodomain
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DNA-binding activity of Nk2.5; however, the outcome
of phosphorylation on transcriptional activity is not
clear (11).
The proline-rich homeodomain (PRH) protein (also
known as Hex) regulates both cell diﬀerentiation and
cell proliferation (13,14). PRH is critical for many pro-
cesses in embryonic development including embryonic
patterning, formation of head, forebrain, thyroid and
liver and heart and development of the vasculature
(15–18). PRH also has a number of functions in the
adult including that of a regulator of haematopoiesis
(19–24). Exogenous expression of PRH inhibits cell pro-
liferation and cellular transformation of haematopoietic
cells of myeloid lineage (21,23). However, PRH can also
function as an oncoprotein in haematopoietic cells of
T-cell lineage (22,25). Interestingly, PRH can both acti-
vate and repress transcription and regulate mRNA trans-
port (23,26). Our recent work has shown that PRH is
oligomeric in vitro and in cells (27). The protein appears
to consist of three domains: an N-terminal domain that
is 20% proline, a central homeodomain that mediates
binding to DNA, and an acidic C-terminal domain. The
N-terminal domain is required for oligomerization and
for the inhibition of myeloid cell proliferation and cell
transformation by PRH (21,24). The N-terminal domain
contains a region that interacts with the promyelocytic
leukaemia (PML) RING-ﬁnger protein and a region that
interacts with eIF4e in PML nuclear bodies (28). The
interaction between PRH and eIF4E inhibits the transport
of some mRNAs involved in growth regulation (23). The
N-terminal domain also contains two regions that confer
the ability to repress transcription (29). An Eh1 motif
located within the ﬁrst 46 amino acids of this domain
mediates the binding of PRH to members of the
Groucho/TLE family of co-repressor proteins and thereby
allows PRH to recruit TLE co-repressor proteins (30).
Binding of PRH to TLE proteins results in the increased
phosphorylation and nuclear retention of TLE proteins
resulting in transcriptional repression by the PRH-TLE
complex (30,31). A second region within the N-terminal
domain (amino acids 46–131) is able to repress transcrip-
tion in the absence of the ﬁrst 46 amino acids although
with less eﬃciency (29,32). The PRH homeodomain
can repress transcription independently of the N-terminal
domain by binding to TATA box sequences and compet-
ing with the TATA box binding protein for these sites
(29). PRH can also bind to TBP and this may also inhibit
transcription by blocking assembly of the pre-initiation
complex (29). In addition, PRH can repress transcription
by binding to proteins that would otherwise activate tran-
scription. For example, PRH binds to c-jun and blocks the
ability of c-jun to activate transcription (33). Similarly,
PRH binds to GATA-2 and prevents this protein from
activating transcription although in this case, PRH inhib-
its the binding of GATA-2 to DNA (34). The C-terminal
domain of PRH has been less intensively characterized
but is reported to be required for the activation of tran-
scription by PRH in haematopoietic cells (35).
Here we demonstrate that PRH interacts with CK2b.
We show that CK2 phosphorylates PRH in vitro and in
cells and that phosphorylation inhibits the DNA-binding
activity of PRH in vitro. We map two sites of CK2 phos-
phorylation in the PRH homeodomain and we show that
phosphorylation of these sites blocks the DNA-binding
activity of PRH in vitro and inhibits transcriptional repres-
sion by PRH in cells.
MATERIALS AND METHODS
Yeast two hybrid screen
A human Erythroleukaemia Matchmaker cDNA library
prepared from K562 cells in pACT2 was obtained from
Clontech and ampliﬁed once before screening.
pACT2-CK2b was isolated from the library and encodes
the CK2bcDNA (amino acids 1–215) cloned in frame with
GAL4 activation domain (AD). pAS2-1-HPRH (1–271),
pAS2-1-PRHN1–132 and pAS2-1-PRHN1–98 encode the
full-length human PRH protein and truncated PRH
proteins fused to GAL4 DBD and have been described
previously (36). The plasmid pGAD-424-TLE1 encodes
human TLE1 (amino acids 1–770) fused to GAL4 AD
and has been described previously (37). The yeast two-
hybrid screen was carried out in yeast strain CG1945 as
described in the Clontech manual.
Expression vectors used in this study
The plasmid pTrcA-His-Myc-PRH expresses Myc and
His-taggedhumanPRH(27)inbacterialcells.Theplasmid
pTrcAHisPRH expresses His-tagged avian PRH (38),
whereas pTrcAHisPRH-HDC expresses His-tagged
avian PRH lacking the N-terminal domain (29) and
pTrcAHisPRH-HD expresses the His-tagged PRH homeo-
domain alone (39). The nucleotides encoding amino acids
S163 and S177 within the pTrcAHisPRH HD construct
were mutated using a QuikChange Mutagenesis kit
(Stratagene) according to the manufacturer’s instructions.
This created pTrcAHisPRH-HD S163E, pTrcAHisPRH-
HD S177E and the double mutant pTrcAHisPRH-HD
S163E/S177E. pBSKS-CK2b20-215 was created by subclon-
ing an EcoRI–XhoI fragment that encodes CK2b (amino
acids 20–215) from pACT2-CK2b into pBSKS
(Stratagene). The plasmid pMUG1-Myc-PRH expresses
Myc-tagged human PRH protein (amino acid residues 7–
270) under the control of the CMV promoter (30). The
plasmid pCS2-HA-Hex expresses HA-tagged murine
PRH and was a kind gift from Dr. Josh Brickman
(University of Edinburgh). The pMUG1-Myc-PRH
S163E plasmid was constructed by digesting pMUG1-
Myc-PRH with StuI and PstI to release an StuI–PstI
PRHfragment. AnewStuI–PstIPRHfragmentcontaining
the mutation S163E was generated by PCR using the for-
wardandreverseoligonucleotideprimersshownbelow(the
mutation is underlined in the reverse primer): 50 TTGCAG
AGGCCTCTGCATAAAAAG 30 and 50 CTGAGCTGC
AGCATCTTGGCCAGACGCTTCCTCTCGGGCGG
TTCGAGATA TTCTGCG 30. After digestion with StuI
and PstI the PCR fragment was inserted into the cut
pMUG-Myc-PRH plasmid. The pMUG1-Myc-PRH
S177E and S163E/S177E double mutant plasmids were
constructed using a QuikChange Mutagenesis kit to
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and pMUG1-Myc-PRH S163E, respectively. All of the
mutants were fully sequenced to conﬁrm the sequence
changes. Plasmids expressing human and avian GST-
PRH fusion proteins have been described previously (30).
The plasmids pRc/CMV-CK2a-HA (40), pRc/CMV-HA-
CK2b (41) and pRc/CMV-CK2a-K68M-HA (42) express
HA-tagged CK a and b subunits and a kinase-dead CK2a
mutant respectively and were a kind gift from Professor
David Litchﬁeld (University of Ontario).
Cell culture and transient co-transfections
K562 cells were grown in glutamine-supplemented
Dulbecco’s modiﬁed Eagle’s medium (Sigma) with 10%
fetal calf serum at 378C and 5% CO2. The cells were tran-
siently co-transfected by electroporation using a Bio-Rad
Genepulser exactly as described previously (29). For
repression assays K562 cells were co-transfected with a
reporter plasmid containing the luciferase gene down-
stream of the minimal TK promoter and ﬁve PRH binding
sites (pTK-PRH) and either pMUG1 vector or the
pMUG1-Myc-PRH plasmids described above. Twenty-
four hours post-transfection, the cells were harvested by
centrifugation and luciferase activity assayed using
the Promega Luciferase Assay System according to the
manufacturer’s instructions. A plasmid expressing
b-galactosidase was included in each transfection to con-
trol for transfection eﬃciency.
Quantitative RT-PCR
K562 cells were treated with DMAT (80mM) or DMSO
for 24h at 378C and 5% CO2. RNA from 5 10
6 cells was
obtained using an RNAeasy1 kit (Qiagen) according to
the manufacturer’s instructions. Reverse transcription
was performed using Superscript3 according to the stan-
dard protocol (Invitrogen). Quantitative PCR was per-
formed by using the ﬂuorescent dye SYBR Green
Master Mix (SensiMix Quantase). The primers used for
the PCR are as follows: neuropilin-1 forward 50 ATT GG
CGTGACTTCCTGCATCG 30 and neuropilin-1 reverse
50 TGTGCTGAGGT TATCGCGGCTG 30; GAPDH
forward 50 TGATGACATCAAGAAGGTGGTGAAG
30 GAPDH reverse 50 TCCTTGGAGGC CATGTGGG
CCAT 30. All PCR reactions were performed in triplicate
and the experiment was repeated three times. The data
were analysed using Rotorgene 6 Software (Corbett
Research, Rotorgene RG-3000). GAPDH was used as
the internal control. Results for relative expression ratios
were calculated according to the Eﬃciency Calibrated
Mathematical Model (43).
Protein purification
Expression and puriﬁcation of the GST-PRH fusion pro-
teins and His-tagged PRH fusion proteins was carried out
as described previously (30,39). The proteins are shown
in Figure S1 and Figure 5B.
Circular dichroism
Circular dichroism (CD) spectra of the PRH HD proteins
(0–2mg/ml in 25mM phosphate buﬀer pH 7.9) were
obtained using a JY CD6 CD spectrometer with 2-mm
path length cells. Spectra were collected between 190
and 260nm at 1-nm increments, using a 2-s integration
time.
Co-immunoprecipitation and western blotting
Rabbit anti-PRH antibodies were prepared using full-
length avian PRH puriﬁed from bacteria as antigen and
bleeds collected from two animals. ELISA was used to
detect high-aﬃnity polyclonal antibodies to the PRH pro-
tein. In western blotting experiments antisera obtained
after the thirdbleed were able to detect human PRH
present in whole-cell extracts from K562 cells and Myc-
and HA-tagged PRH in transiently transfected cells
(Figure S2A). For western blotting, rabbit polyclonal
antibodies were used at 1/2500 dilution with  50-mg
whole-cell extract loaded on the gel. We have described
previously the production and use of mouse polyclonal
antisera that recognizes PRH in cell extracts (21). As
expected, these antisera recognize human Myc-tagged
PRH as well as murine HA-tagged PRH in transiently
transfected cells (Figure S2B). The expression levels of
the Myc-PRH and Myc-PRH mutant proteins used in
this study were determined by western blotting with the
Myc9E10 antibody (Santa Cruz Biotechnology). The
western membranes were also probed with a Tubulin anti-
body (mouse monoclonal MS-581-P1 NeoMarkers) to
conﬁrm equal protein loading and transfer.
To examine PRH phosphorylation, whole-cell extracts
were prepared from 5 10
6 K562 cells incubated with
80-mM DMAT (Calbiochem) or 150mM TBB
(Calbiochem) in DMSO for 24h at 378C or the equivalent
volume of DMSO. Whole-cell extracts were then prepared
by re-suspending the cells in lysis buﬀer (50mM Tris pH 8,
100mM NaCl, 20mM NaF, 10mM KH2PO4,1 m M
DTT, 1% Triton, 10% glycerol) for 30min at 48C.
Protein concentration in the lysates was measured using
a Bradford assay and equal amounts of protein were
immuno-blotted onto Immobilon-P membrane and ana-
lysed by western blot using the mouse and rabbit PRH
antisera described above.
For co-immunoprecipitation assays, K562 cells were
co-transfected with pMUG1-Myc-PRH and the CK2
expression vectors described previously. Whole-cell
extracts were then prepared and equal amounts of total
protein added to an equivalent volume of binding buﬀer
(50mM Tris pH 8, 100mM KCl, 0.1mM EDTA, 2mM
DTT, 0.2% NP-40, 0.1% bovine serum albumin (BSA),
2.5% glycerol) before incubation with anti-HA antibodies
(Clone 12CA5 from Roche) for 1h at 48C with agitation.
Protein G beads (Sigma) were incubated with the extracts
for a further 2h at 48C. The beads were then collected by
centrifugation and washed three times in wash buﬀer
(50mM Tris, pH 8, 200mM NaCl, 2mM DTT, 0.5%
NP-40) at 48C. All buﬀers and washes contained protease
inhibitor cocktail (Roche) and phosphatase inhibitor
cocktail (50mM NaF, 1mM Na3VO4,1 0 m MN a
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phosphate). After SDS–PAGE, the proteins were
immuno-blotted onto Immobilon-P membrane, and
Myc-tagged PRH was detected using the Myc9E10 anti-
body (Santa Cruz Biotechnology).
Pull-down assays
In vitro pull-down assays were performed using GST-PRH
fusion proteins and His-tagged PRH fusion proteins with
in vitro transcribed and translated CK2b. Approximately
20mg of each GST fusion protein or an equimolar amount
of GST was bound to 50ml glutathione-Sepharose 4B
beads (Sigma) according to the manufacturer’s instruc-
tions. Approximately 20mg of each His-tagged PRH pro-
tein was bound to 50ml His-Select
TM Nickel-Aﬃnity gel
(Sigma) according to the manufacturer’s instructions.
CK2b labelled with [
35S]methionine was produced
using pRc/CMV-HA-CK2b or pBSKS-CK2b20-215 and a
TNT Quick Coupled Transcription/Translation system
(Promega) according to the manufacturer’s protocol.
Labelled CK2b was incubated with the functionalized
beads in binding buﬀer (20mM HEPES pH 7.8, 200mM
KCl, 5mM MgCl2, 0.5mM dithiothreitol, 0.5% NP-40,
50ng/ml BSA) for 3h at 48C. After extensive washing
in binding buﬀer, bound proteins were eluted in boiling
protein sample buﬀer containing 1% SDS and analysed by
SDS–PAGE and ﬂuorography.
Protein phosphorylation and dephosphorylation
Puriﬁed PRH protein, truncated PRH proteins and PRH
mutants (10ng) were incubated in CK2 phosphorylation
buﬀer (50mM KCl, 10mM MgCl2, 20mM Tris–HCl
pH 7.5, 200mM ATP) with 100U CK2 enzyme (500U/ml
Calbiochem) for 30min at 308C. Dephosphorylation
was brought about by incubation of the phosphorylated
protein with 10U of calf alkaline phosphatase (CAP)
(6U/ml Promega) in CAP buﬀer (50mM Tris–HCl pH
9.3, 10mM MgCl2, 1mM ZnCl2, 10mM spermidine) for
20min at 258C.
EMSA
The double-stranded PRH-binding site shown below
(400ng) was labelled with [a
32]P dATP using Klenow
enzyme.
50AGCTTCTGGGAAGCAATTAAAAAATGGCTCGAGCT 30
30 AGACCCTTCGTTAATTTTTTACCGAGC 50
After the removal of unincorporated [a
32]P dATP using
a Micro Bio-Spin 6 column (Bio-Rad), the labelled oligo-
nucleotide (100pM) was incubated with His-tagged pro-
teins in 20mM Tris pH 8.0, 50mM NaCl, 1mM MgCl2,
1mM dithiothreitol, 0.5mg/ml BSA and 10% glycerol at
48C for 30min. Free and bound DNA were separated on
5% non-denaturing polyacrylamide gels run in 1 TAE
and visualized using a PhosphorImager and ImageQuant
3.3 software (Molecular Dynamics).
Mass spectroscopy
Proteins were excised from SDS-PAGE gels and destained
using three 30-min washes in 150ml of 50:50 (v/v) acetoni-
trile (ACN):25mM NH4CO3 at 228C. The gel slices
were then dried down before the addition of 5ml trypsin
(0.1mg/ml Calbiochem in 1% acetic acid) and 25mlo f
NH4CO3 pH 8. After incubation overnight at 378C, pep-
tides were extracted using three 30-min washes in 30ml
50:50 (v/v) ACN:5% TFA at 228C. After being dried
down, the peptides were re-suspended in 5ml 0.1% TFA/
5%ACN before analysis. Proteins were initially identiﬁed
using MALDI mass spectroscopy. Phosphopeptides were
identiﬁed using an IMAC30 ProteinChip (CIPHERGEN)
charged with gallium metal ions in a CIPHERGEN
ProteinChip reader, controlled by ProteinChip software
(version 3.2.1).
RESULTS AND DISCUSSION
PRH interacts with CK2b
We used a yeast two-hybrid screen to identify proteins
that interact with PRH. This screen utilized a human
erythroleukaemia matchmaker cDNA library derived
from K562 cells and a plasmid that expresses PRH fused
to the GAL4 DNA-binding domain (DBD) (36). Yeast
cells that express both PRH and a protein that interacts
with PRH were identiﬁed on the basis of b-galactosidase
activity and histidine prototrophy (data not shown). The
screen resulted in the isolation of ﬁve diﬀerent cDNA
clones. Sequence analysis identiﬁed one of the ﬁve positive
clones as the regulatory b subunit of protein kinase CK2.
In order to conﬁrm that PRH interacts with CK2b,w e
made use of constructs in which amino acids 1–132 or
1–98 from PRH are fused to the GAL4 DBD and a con-
struct in which CK2b is fused to the GAL4 activation
domain (AD) (Figure 1A). None of these constructs
alone is capable of inducing b-galactosidase activity in
yeast (Figure 1B, columns 1–3). However, co-expression
of the constructs expressing PRH fusion proteins and
CK2b fusion proteins in yeast cells produces signiﬁcant
levels of b-galactosidase activity (Figure 1B, columns
4 and 5). Similarly, the constructs expressing the GAL4
PRH fusion proteins produce signiﬁcant b-galactosidase
activity when co-expressed with a fusion protein consisting
of the co-repressor protein TLE1 fused to GAL4 AD
(Figure 1B, columns 7 and 8). We conclude that amino
acids 1–98 within the N-terminal domain of PRH are suf-
ﬁcient to interact with CK2b in yeast cells and that this
interaction is comparable to the previously characterized
interaction between the PRH N-terminal domain and the
co-repressor protein TLE1 (30).
PRH and CK2b interact in vitro and in cells
To determine whether CK2b interacts with PRH in vitro
we carried out pull-down experiments. In order to deter-
mine whether any interaction is conserved, we made use
of human and avian PRH-GST fusion proteins. The
N-terminal domain of human PRH (amino acids 1–132)
and avian PRH (amino acids 1–141) were expressed in
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glutathione-Sepharose beads (Figure S1). The cDNA cor-
responding to CK2b was transcribed and translated
in vitro to produce
35S-labelled CK2b Glutathione beads
carrying GST or the GST-PRH N proteins were incubated
with labelled CK2b and then washed extensively. Bound
protein was eluted by boiling in SDS–PAGE loading
buﬀer and analysed by SDS–PAGE. Figure 1C shows
that labelled CK2b binds to the avian GST-PRH N
1-141 (lane 3) and human GST-PRH N 1-132 (lane 4)
fusion proteins but binds only very weakly, if at all, to
GST alone (lane 2). These data show that the N-terminal
domains of human and avian PRH bind to CK2b in vitro.
In order to conﬁrm that the GST tag is not responsible
for the interaction with CK2b and to map any further
CK2-interacting regions within PRH, we next performed
pull-down assays with histidine-tagged full-length human
PRH and histidine-tagged truncated PRH proteins
(Figure S1). Nickel-agarose beads carrying histidine-
tagged full-length PRH or histidine-tagged truncated
PRH proteins were incubated with labelled CK2b and
then washed extensively as described above. Bound
CK2b was then eluted and analysed by SDS–PAGE
as before. Figure 1D shows that as expected, labelled
CK2b binds to the full-length human PRH protein
(lane 3). However, labelled CK2b also binds to a
truncated PRH protein lacking the N-terminal domain
(lane 4) and to a truncated protein corresponding to the
PRH homeodomain alone (lane 5). These data suggest
that CK2b can bind independently to the PRH N-terminal
domain and the PRH homeodomain. Removal of PRH
sequences from the beads by protease digestion con-
ﬁrmed that CK2b does not bind to the His-tag sequence
(data not shown).
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Figure 1. PRH interacts with CK2b in yeast and in vitro.( A) A schematic representation of the PRH protein (top line) and the fusion proteins
expressed in yeast cells. Proline Rich indicates the N-terminal repression domain, HD indicates the homeoodomain and C indicates the acidic
C-terminal domain. Sequences from the N-terminal region of PRH were fused to the GAL4 DNA-binding domain (G4 DBD). Amino acids 1–215 of
CK2b subunit and 1–770 of human TLE1 were fused to the GAL4 activation domain (G4 AD). (B) A bar chart showing the b-galactosidase activity
obtained after transformation of yeast strain MaV203 with the constructs indicated. D Represents G4 DBD; A represents G4 AD. The results shown
are the mean and standard deviation from three experiments. (C) The results of a pull-down experiment with in vitro transcribed and translated
CK2b (lane 1) incubated with glutathione beads coated with GST (lane 2), GST-human PRH N 1–132 (3), or GST-avian PRH N 1–141. Bound
proteins were eluted using glutathione, separated by SDS–PAGE and visualized using ﬂuorography and a PhosphorImager. (D) The results of a pull-
down experiment with in vitro transcribed and translated CK2b (lane 1) incubated with nickel agarose beads (lane 2) or beads coated with His-tagged
PRH (lane 3), His-tagged PRH-HDC (lane 4) and His-tagged PRH-HD (lane 5). Bound proteins were eluted by boiling and visualized as described
above. (E) The results of a co-immunoprecipitation assay in which K562 cells were transiently transfected with plasmids expressing Myc-tagged PRH
(lanes 2–5), HA-tagged CK2b (lanes 3–5), CK2a (lane 3) and CK2aK68M (lane 4). Proteins were precipitated with HA antibodies and then western
blotted for PRH (top panel) and CK2a and CK2b (bottom panel) using Myc and HA antibodies, respectively.
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ous PRH and CK2b from mammalian cells were unsuc-
cessful possibly due to low protein levels (data not shown).
However, we were able to co-immunoprecipitate epitope-
tagged PRH and CK2b. We transiently
co-transfected K562 cells with vectors expressing Myc epi-
tope tagged PRH, HA-tagged CK2b and HA-tagged
CK2a. Forty-eight hours post-transfection we immuno-
precipitated CK2 using HA antibodies and then assayed
for co-immunoprecipitation of Myc-PRH by western blot-
ting with a Myc antibody (Figure 1E). As can be seen from
the data, Myc-PRH co-immunoprecipitates when an HA
antibody is added to lysates prepared from cells expressing
HA-tagged CK2a and CK2b (Figure 1E, lane 3) or CK2b
alone (lane 5), but is not immunoprecipitated from cells
that are not expressing HA-tagged CK2 subunits (lanes 1
and 2). Interestingly, PRH is not immunoprecipitated
from cells expressing CK2b and an HA-tagged kinase
dead CK2a mutant CK2aK68M (lane 4). We conclude
that PRH and CK2b interact in cells. In addition, these
data suggest that the presence of kinase dead CK2a inhib-
its the PRH-CKb interaction and/or that phosphorylation
of PRH is important for the interaction.
PRH is a phosphoprotein in cells
To investigate the phosphorylation of PRH in cells,
we ﬁrst immunoprecipitated Myc-tagged PRH from
transiently transfected K562 cells using a monoclonal
Myc 9E10 antibody. The proteins in the immunoprecipi-
tate were separated by SDS–PAGE and visualized by
staining with Pro-Q diamond phosphoprotein stain and
subsequently with SYPRO Ruby protein stain
(Figure 2A). The immunoprecipitated proteins were cut
from a stained gel and identiﬁed using mass spectroscopy.
Three bands contained peptides that originate from PRH.
However, only the slowest migrating and most prominent
PRH band is stained by Pro-Q Diamond, a reagent that
binds speciﬁcally to phosphorylated proteins (Figure 2A).
We conclude that Myc-PRH is a phosphoprotein in cells.
To examine whether endogenous PRH is phosphory-
lated by CK2 we ﬁrst generated polyclonal anti-PRH
antibodies in rabbits. In western blotting experiments,
the rabbit antisera are able to detect a 37-kDa protein
present in K562 nuclear extracts (Figure S2A). We con-
ﬁrmed that this protein is PRH by over-expressing HA-
and Myc-tagged PRH proteins and showing that the
tagged proteins are also detected by the rabbit antisera
(Figure S2A, lanes 2 and 3). Polyclonal mouse anti-PRH
antisera also detect endogenous PRH and the tagged PRH
proteins in whole-cell extracts (Figure S2B). We then
tested the ability of the rabbit and mouse antisera to rec-
ognize PRH that has been incubated with CK2 and ATP
or CK2 and ATP followed by CAP. As expected, both
antisera recognize puriﬁed PRH; this is shown in
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Figure 2. PRH is a phosphoprotein in cells. Myc-tagged PRH was immunoprecipitated from K562 cells and run on an SDS–PAGE gel. (A) The
precipitated proteins were stained using SYPRO Ruby (left panel). HC and LC indicate heavy and light antibody chains, respectively.
Phosphorylated PRH was identiﬁed by staining with Pro-Q Diamond. (right panel). (B) Untreated PRH (1) and PRH treated with either CK2
and ATP (2) or CK2 and ATP and then CAP (3) were separated by SDS–PAGE and western blotted using mouse anti-PRH antisera (top). The
membrane was stripped and reprobed using rabbit anti-PRH antisera (middle) and then stripped and reprobed using a CK2 antibody as a control for
protein loading (bottom). (C) K562 cells were treated with 80mM DMAT or 150mM TBB or equivalent volumes of DMSO and incubated for 24h at
378C. Whole-cell extracts were then prepared and examined for PRH by western blot using the mouse anti-PRH antisera (top). The membrane was
ﬁrst stripped and reprobed using rabbit anti-PRH antisera (middle) and then stripped and reprobed using a LaminA/C antibody as a control for
protein loading (bottom). (D) K562 cells were treated with 80mM DMAT or DMSO for 24h. The cells were then harvested and RNA isolated for
quantitative RT-PCR analysis. The data were normalized to GAPDH gene expression. The results presented are the average and standard deviation
of three independent experiments.
Nucleic Acids Research, 2009,Vol.37, No. 10 3293Figure 2B where a membrane was ﬁrst probed with the
mouse antisera (Figure 2B, top panel), and then stripped
and reprobed with the rabbit antisera (middle panel).
However, the mouse antisera fail to bind, or bind very
poorly, to PRH that has been incubated with CK2 and
ATP (Figure 2B, top panel, lane 2). Incubation with CAP
restores binding of the mouse antisera and induces a slight
increase in the mobility of the PRH band (Figure 2B, top
panel, lane 3). Conversely, the rabbit anti-PRH antisera
bind to PRH that has been incubated with CK2 and ATP
but does not bind to PRH that has been incubated with
CAP (Figure 2B, middle panel, lanes 2 and 3). These data
indicate that the mouse and rabbit anti-PRH antisera
preferentially bind to diﬀerent forms of PRH. The
mouse antisera appear to bind preferentially to unphos-
phorylated PRH, whereas the rabbit antisera appear to
bind preferentially to CK2-phosphorylated PRH. It
would seem unlikely that the rabbit antisera are phospho-
speciﬁc since it also recognizes PRH produced in bacterial
cells. More likely, these antisera diﬀerentially recognize
conformational states of PRH that are altered or pro-
duced by phosphorylation.
We next used the mouse and rabbit anti-PRH antisera
to examine eﬀects of two CK2 inhibitors on PRH in cells.
We incubated K562 cells with the CK2 inhibitors DMAT
and TBB for 24h. The cells were then harvested and
used to prepare whole-cell extracts for western blotting.
Treatment with either inhibitor had no eﬀect on the levels
of PRH detected in these extracts using the mouse antisera
(Figure 2C, top panel). However, both DMAT and TBB
signiﬁcantly reduced the amount of PRH detected after
stripping the blot and reprobing with the rabbit antisera
(Figure 2C, middle panel). Further stripping and reprob-
ing with a LaminA/C antibody conﬁrms equal protein
loading in each lane (Figure 2C, bottom panel). Since
we have shown that the rabbit antisera bind preferentially
to CK2-phosphorylated PRH, we conclude that endo-
genous PRH is phosphorylated by endogenous CK2 in
K562 cells.
To determine the functional consequence of the phos-
phorylation of PRH by CK2 in cells, we looked at the
eﬀect of DMAT on a PRH target gene. K562 cells were
incubated with and without DMAT for 24h and mRNA
was extracted for analysis by quantitative RT-PCR.
Figure 2D shows the relative mRNA levels of the PRH
regulated gene, neuropilin-1 (20,44), under these con-
ditions. Incubation of cells with DMAT results in a
signiﬁcant decrease in neuropilin-1 gene expression
(Figure 2D, column 4). Since this gene is a target for
repression by PRH (20,44), we conclude that the loss
of PRH phosphorylation by CK2, results in more tran-
scriptionally active PRH being present in the cell and, as a
consequence, decreased expression of this PRH target
gene.
Phosphorylation by CK2 inhibits PRH DNA-binding
activity
To determine whether phosphorylation by CK2 has an
eﬀect on DNA binding by PRH, we puriﬁed full-length
human and avian histidine-tagged PRH and performed
EMSA after incubation of the proteins with CK2 and
ATP. In the absence of CK2 and ATP, human PRH
binds to DNA to form a complex with retarded mobility
(Figure 3, lane 2). Incubation of PRH with CK2 alone or
with ATP alone prior to EMSA, results in a slight
decrease in the DNA-binding activity of PRH (Figure 3,
lanes 3 and 4). In contrast, incubation of PRH with both
CK2 and ATP prior to EMSA results in the almost com-
plete loss of DNA-binding activity (Figure 3, lane 5). If,
however, the PRH protein treated with CK2 and ATP is
incubated with CAP prior to EMSA, full DNA-binding
activity is restored (Figure 3, lane 6). Identical results were
obtained for the avian PRH protein (data not shown).
We conclude that phosphorylation by CK2 acts as a
reversible switch for the DNA-binding activity of PRH.
These data suggest that the interaction of CK2 with
PRH in the absence of phosphorylation has little eﬀect
on DNA binding.
Phosphorylation of the PRH homeodomain is sufficient
to inhibit DNA binding
Inspection of the amino acid sequence of PRH reveals
several consensus CK2 sites that are conserved between
the human and avian proteins. To investigate the impor-
tance of these or other phosphorylation sites in the inhi-
bition of DNA binding, we made use of two truncated
PRH proteins consisting of the PRH homeodomain and
C-terminal domain (PRH-HDC) and the PRH homeodo-
main alone (PRH-HD), respectively (Figure 4A). The
eﬀects of phosphorylation on the DNA-binding activity
Free 
DNA
PRH-DNA
–+++++
––+–++
–––+++
–––––+
PRH 
CK2 
ATP 
CAP
123456
Figure 3. CK2 phosphorylates PRH and inhibits DNA binding. A rep-
resentative EMSA showing the eﬀects of CK2 and ATP on the binding
of PRH to a labelled oligonucleotide carrying a PRH-binding site.
Untreated PRH (2) or PRH pre-incubated with CK2 alone (3), ATP
alone (4) or CK2 and ATP (5), were incubated with the labelled DNA
for 30min at 228C. Free and bound labelled DNA were then separated
on a 6% non-denaturing polyacrylamide gel and visualized using a
PhosphorImager. To examine the eﬀect of dephosphorylation, PRH
that had been pre-incubated with CK2 and ATP was incubated with
CAP (6).
3294 Nucleic Acids Research, 2009, Vol. 37,No. 10of these proteins were analysed using EMSA as described
previously for the full-length protein. Figure 4B and
C show that both PRH-HDC and PRH-HD are able to
bind DNA. The DNA-binding activity of both of these
proteins is somewhat reduced after incubation with CK2
alone. However, the DNA-binding activity of both pro-
teins is abolished after incubation with both CK2 and
ATP (Figure 4B and C, lane 4). Furthermore, in both
cases incubation with CAP after treatment with CK2
and ATP, results in the restoration of DNA-binding activ-
ity (Figure 4B and C, lane 5). These data demonstrate
that phosphorylation of the homeodomain alone is suﬃ-
cient to inhibit the DNA-binding activity of PRH and that
as in the case of the full-length protein, the eﬀects of
phosphorylation are readily reversible.
CK2 phosphorylates two serine residues within the
PRH-HD
To identify amino acids in PRH that are phosphory-
lated by CK2, we made use of surface-enhanced laser
desorption/ionisation time-of-ﬂight mass spectrometry
(SELDI-TOF-MS). Phosphorylated PRH was obtained
by incubating puriﬁed full-length human PRH with
CK2 and ATP. Samples of the phosphorylated and
unphosphorylated PRH protein were then analysed
by SDS–PAGE. Gel slices corresponding to the
phosphorylated protein were excised from the gel and
incubated with trypsin. In order to preferentially retain
phosphopeptides, the tryptic peptides were extracted
from the gel slice and applied to the active spot of an
IMAC30 ProteinChip array charged with gallium ions.
After on-spot washing, the IMAC30 array was placed in
a ProteinChip reader and the masses of the retained pep-
tides were obtained by SELDI-TOF-MS. A peptide with
m/z 2829.5 was preferentially retained on the IMAC sur-
face and is therefore probably phosphorylated. A theoret-
ical trypsin digest performed on the PRH amino acid
sequence using ProteinProspector did not identify this
peptide. However, when the possible phosphorylation
events are taken into account, the m/z 2829.5 peak corre-
sponds to the peptide:
This phosphopeptide is from within the homeodomain
of PRH and contains a consensus CK2 site at S163 and
a non-consensus CK2 site at S177. These two serine resi-
dues (highlighted in bold) appear to be phosphorylated
adding a mass of 160Da (2 80 for the phosphoryl
group) to the non-phosphorylated peptide (2672.21)
and giving a total mass of 2832.2Da, which is very close
to the measured peak 2829.5 (with a deviation of 2.7).
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Figure 4. Phosphorylation of the homeodomain inhibits DNA binding. (A) A schematic representation of the full-length PRH protein (top line) and
the truncated PRH proteins (second line) used in this study. Labels and numbering are as shown in Figure 1. The ﬁlled rectangle represents a
histidine tag. The experiment shown in Figure 3 was repeated using the PRH-HDC (B) and PRH-HD (C) proteins.
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from PRH did not produce any masses close to the
observed value of 2829.5Da. Taken together, these data
suggest that CK2 phosphorylates PRH on both S163 and
S177. Phosphorylation of either or both of these amino
acids could be responsible for the abrogation of DNA-
binding activity by CK2.
Phosphorylation of S163 and/or S177 inhibits DNA binding
To examine the eﬀects of phosphorylation at S163 and
S177 on PRH, we mutated these positions to alanine
to prevent phosphorylation, or glutamic acid to mimic
phosphorylation, either individually or in combination
(Figure. 5A). The mutations were initially produced in
the context of the PRH-HD protein construct using site-
directed mutagenesis. These mutated proteins were then
expressed in bacteria and puriﬁed as described previously
(39). However, in each case, mutation to alanine resulted
in very low yields of the homeodomain protein and
consequently very low levels of DNA binding. We will
therefore present data obtained using the glutamic acid
mutants.
Equal amounts of the wild-type and mutated proteins
were incubated with CK2 and ATP and then examined by
SDS–PAGE (Figure 5B). The resulting gel was stained
with Pro-Q Diamond Phosphoprotein Stain to assess pro-
tein phosphorylation followed by staining with Coomassie
blue to assess the amount of protein loaded in each lane.
Coomassie staining indicates that equal amounts of pro-
tein were loaded (Figure 5B, bottom panel). Staining for
phosphoproteins reveals that the wild-type PRH HD is
phosphorylated by CK2 (Figure 5B, top panel, lane 2).
However, the S163E and S177E proteins are less strongly
stained suggesting that they are partially phosphorylated
(Figure 5B, top panel, lanes 3 and 4). This implies that
each single mutant is phosphorylated by CK2 at the
unmutated site. In contrast, the S163E/S177E double
mutant is very poorly stained suggesting that this protein
is not phosphorylated. These data suggest that there are
no additional CK2 sites within the homeodomain or that
if any additional sites are present they are dependent on
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Figure 5. Mutation of S163 or S177 to glutamic acid inhibits DNA binding. (A) A schematic representation of the PRH derivatives used in these
experiments. The PRH-HD protein was mutated at S163 and/or S177 as shown in the Figure. (B) The PRH-HD proteins indicated were incubated
with CK2 and ATP (lanes 2–5) or CK2, ATP and CAP (lanes 7–10) before analysis by SDS–PAGE. The top panel shows the results of staining with
Pro-Q Diamond Phosphoprotein Stain. The bottom panel shows the results of staining for total protein with Coomassie blue. Lanes 1 and 6 contain
protein markers (20, 14 and 6.5kDa). (C) A representative EMSA showing the binding of PRH-HD and the mutated HD proteins to a DNA
fragment carrying a single PRH site. In each case, the protein concentrations used were 12.5, 25 and 50nM and free and bound DNA were separated
and visualized exactly as described in Figure 3. (D) An experiment showing the eﬀects of CK2 and ATP on the DNA-binding activity of the PRH-
HD, S163E and S177E proteins. In each case, the protein–DNA complexes were stabilized by increasing the protein concentration to 150nM,
carrying out the binding reaction at 48C and running the EMSA gel at 48C overnight. In each case, (1) is untreated PRH, (2) is PRH pre-incubated
with CK2 and ATP and (3) is PRH pre-incubated with CK2 and ATP and then treated with CAP.
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phosphorylation is reversible we incubated the wild-type
and mutated proteins with CK2 and ATP and then treated
the phosphorylated proteins with CAP. Treatment with
CAP brings about dephosphorylation of the wild-type
PRH HD protein (Figure 5B, top panel, lane 7).
Interestingly the phosphorylated S163E and S177E
mutants appear to be only partially dephosphorylated
after treatment with CAP (Figure 5B, top panel, lanes 8
and 9). It is possible that in each case the introduced
glutamic acid residue might impair the ability of CAP to
dephosphorylate the neighbouring serine residue.
To investigate the DNA-binding activity of the mutated
proteins, increasing equivalent amounts of each were
added to a labelled DNA carrying a PRH-binding site
and the free and bound DNA separated as described
above. As expected, the wild-type protein binds to the
labelled DNA (Figure 5C, lanes 2–4). In contrast, there
was poor binding of PRH HD S163E protein to this DNA
(Figure 5C, lanes 5–7). The PRH HD S177E protein and
the double mutant PRH HD S163E/S177E did not bind
DNA under the conditions used in these experiments
(Figure 5C, lanes 8–13). These data suggest that phos-
phorylation at S177 abolishes DNA binding while phos-
phorylation at S163 only partially blocks DNA binding.
However, it is possible that the S163E mutation does not
accurately mimic the eﬀects of phosphorylation due to the
ﬂexibility of the glutamic acid side chain. Furthermore,
it is also possible that the S177E mutant and the S163E/
S177E double mutant are unstable or unfolded. In order
to discount the latter possibility, we examined the folding
of all four proteins using CD. The CD spectra obtained
were identical indicating that each protein has similar
secondary structure (data not shown).
In order to determine whether the DNA-binding activ-
ity of the mutated proteins could be stabilized we
increased the protein concentration, formed the complexes
at 48C and ran the EMSA gels at low temperature. Under
these conditions, the S163E and S177E protein are able
to bind to the PRH site albeit less eﬃciently than the
wild-type protein (Figure 5D, lanes 5 and 8). These data
conﬁrm that the S177E mutation is not suﬃcient to com-
pletely block DNA binding and suggest that phosphoryla-
tion at this position also results in the partial inhibition
of DNA binding. These data also show that the S163E
mutation does not totally abolish DNA binding suggest-
ing that phosphorylation at S163 is also not suﬃcient to
completely block DNA binding. In each case, treatment
with CK2 and ATP signiﬁcantly reduces this residual
DNA-binding activity (Figure 5D, lanes 6 and 9). This
experiment conﬁrms that phosphorylation at both posi-
tions contributes to the inhibition of DNA binding and
that phosphorylation at both positions is required to com-
pletely block DNA binding.
Mutation of S163 and/or S177 inhibits the repression of
transcription by PRH
We next set out to examine the eﬀects of the S163E
and S177E mutations on the ability of PRH to repress
transcription. In order to do this, the S163E and S177E
mutations and the S163E/S177E double mutation were
introduced into the full-length PRH protein in the context
of Myc-PRH fusion proteins (Figure 6A). The wild-type
and mutated full-length proteins were then expressed in
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Figure 6. Mutation of S163 or S177 inhibits transcription repression
by PRH. (A) The top panel shows a schematic representation of the
full-length PRH proteins used in this experiment. Whole-cell extracts
were prepared from K562 cells transiently transfected with vectors
expressing Myc-tagged full-length PRH (1) and vectors expressing
Myc-PRH S163E (2), Myc-PRH S177E (3) or Myc-PRH S163E/
S177E (4). The proteins were then separated by SDS–PAGE and west-
ern blotted for PRH using the Myc9E10 antibody and tubulin using
a mouse monoclonal anti-tubulin antibody as a control for protein
loading. (B) The graph shows the relative promoter activity in K562
cell extracts 24h after transient transfection with a reporter plasmid
in which the luciferase gene is under the control of the minimal
TK promoter and ﬁve upstream PRH-binding sites (pTK-PRH), the
b-galactosidase expression plasmid (pSV-lacZ) and the PRH expression
vectors shown above. Relative promoter activity is the luciferase activ-
ity normalized for transfection eﬃciency using the b-galactosidase activ-
ity. The experiment was performed six times and the values shown are
the means and standard deviation.
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ferase gene under the control of the TK promoter and ﬁve
PRH-binding sites. Western blotting shows that wild-type
and mutated proteins are expressed at equivalent levels in
the transfected cells (Figure 6A). However, although wild-
type PRH represses reporter activity to around 30% of the
unrepressed level (Figure 6B, column 2), the S163E and
S177E mutants and the S163E/S177E double mutant
have greatly reduced repression activity (Figure 6B, col-
umns 3–5). We conclude that these mutations inhibit the
DNA-binding activity of PRH in cells resulting in a reduc-
tion in the ability of these proteins to repress transcription.
CONCLUSIONS AND IMPLICATIONS
Here, we have shown that human and avian PRH bind to
the b subunit of CK2 and that PRH is phosphorylated by
CK2 in vivo. Moreover, we have demonstrated that there
is a decrease in PRH target gene expression in the presence
of an inhibitor of CK2. This suggests that a functional
consequence of phosphorylation of PRH by CK2 is the
inhibition of transcriptional repression by PRH. We have
shown that CK2 phosphorylates PRH at two sites within
the homeodomain. Phosphorylation at these sites inhibits
the DNA-binding activity of PRH in vitro and inhibits the
transcription repression function of this protein in cells.
Although several other homeodomain proteins are sub-
strates for CK2, in these cases phosphorylation generally
occurs outside the homeodomain. The cooperative bind-
ing to DNA of homeodomain proteins Antennapaedia
and Extradenticle, for example, is regulated by CK2 phos-
phorylation of Antennaepaedia at multiple sites outside
the homeodomain (5). Similarly, Engrailed is phosphory-
lated by CK2 at sites outside the homeodomain but in this
case phosphorylation results in increased DNA-binding
activity (8) and the inhibition of inter-cellular traﬃcking
(7). In contrast, phosphorylation of Csx/Nk2.5 by CK2
occurs within the homeodomain at a consensus CK2 site
([S/T]XX[E/D]) conserved among all NK class homeodo-
main proteins and identiﬁed here as a phosphorylation site
S163 in PRH (11). However, in the case of Csx/Nk2.5
phosphorylation results in increased DNA binding (11),
S163 is located at the start of the second helix of the
PRH homeodomain and this residue is not thought to
be involved in binding to DNA. However, model building
suggests that this amino acid in PRH could be in close
approach to the phosphate backbone in the PRH–DNA
complex (Figure 7A). Phosphorylation at this position in
PRH would thus place a negative charge close to the DNA
phosphate backbone and this would be expected to result
in decreased DNA binding. Our mutagenesis data shows
that the replacement of S163 with glutamic acid to mimic
phosphorylation decreases the DNA-binding activity of
PRH but is not suﬃcient to completely block DNA bind-
ing. Surface exposed glutamic acid residues can occupy
several positions due to the ﬂexibility of the side chain,
and this might explain why DNA binding is reduced but
not abolished by this substitution.
Phosphorylation site S177 in PRH has not been iden-
tiﬁed previously in any other homeodomain protein.
This site occurs within the motif SERQ and this sequence
is present at the same position in a number of other home-
odomain proteins, including HoxD4, HoxD3, FTZ,
HoxA6 and others. Model building suggests that S177
is located at the start of the recognition helix in close
proximity in space to Q180 and allowing the formation
of two hydrogen bonds (Figure 7B). The OH group of the
S177 side chain can donate a hydrogen to the O group of
Q180 side chain, the NH group of the S177 main chain can
also donate a hydrogen to the Q180 O group. The NH2
group of the Q180 side chain contacts the phosphate back-
bone of the opposing DNA. Together, these interactions
keep the side chain of Q180 in place to contact the
phosphate backbone of DNA and form a hydrogen
bond network that links S177 to DNA via residue Q180.
Phosphorylation of S177 would disrupt this hydrogen-
bond network and place a negative charge close to the
DNA backbone phosphate. Phosphorylation of S177
would thus be expected to reduce DNA binding. We
have shown that the replacement of S177 with glutamic
acid inhibits the DNA-binding activity of PRH although
the mutant is still able to bind DNA, albeit with severely
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Figure 7. Molecular models of S163 and S177. A molecular model of
the PRH homeodomain–DNA complex based on a 3D alignment of the
PRH homeodomain structure (PDB 1WQ1) and the homeodomain
protein–DNA complexes (PDB 1ENH, 1HDP and 1IG7) was made
using 3D-superimpose in Strap (45) and visualized using PyMOL
(46). (A) The ﬁgure highlights the proximity of S163 to the DNA back-
bone (thick red line). (B) The hydrogen bond network that links S177
to the DNA backbone via Q180. In both images, the pink shading
indicates the volume that would be occupied by phosphoserine.
3298 Nucleic Acids Research, 2009, Vol. 37,No. 10reduced aﬃnity. This could be due to the fact that this
substitution does not accurately mimic the eﬀect of phos-
phorylation or it might mean that phosphorylation at
both S163 and S177 is required to completely block
DNA binding. Certainly, phosphorylation of the S177E
mutant blocks DNA binding and the S163E/S177E
double mutant fails to bind DNA to any signiﬁcant
extent. Since other homeodomain proteins contain poten-
tial phosphorylation sites at positions equivalent to S163
and S177 in PRH, it would seem likely that CK2 could
regulate the DNA-binding activity of other proteins in
a similar manner.
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